As BeiGene gears up for an all-out war against AbbVie and Johnson & Johnson’s Imbruvica, the company has turned in more clinical evidence to show it has the winning BTK inhibitor to fight certain blood cancers.
BeiGene’s Brukinsa trounced Imbruvica at preventing disease progression or death in patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), BeiGene said Wednesday.
The data come from the final analysis of the phase 3 ALPINE trial. In the study, Brukinsa showed superiority as assessed by both an independent data review committee and investigator, according to BeiGene.
Brukinsa’s latest progression-free survival win deals another blow to Imbruvica in the rivals’ upcoming face-off in the all-important CLL/SLL arena. Brukinsa last year showed a statistically significant improvement on tumor shrinkage during an interim analysis of the ALPINE study, thereby hitting the study’s primary endpoint.
BeiGene didn’t share detailed tumor progression data in Wednesday’s announcement. The company’s earlier investigator analysis found that Brukinsa shrank tumors in 78.3% of patients, versus 62.5% in the Imbruvica group, according to results shared at the European Hematology Association 2021 virtual congress. At that time, 94.9% of Brukinsa takers were estimated to be alive without disease progression at one year, versus 84% in the Imbruvica arm, leading to a descriptive risk reduction of 60%.
In addition to efficacy, Brukinsa has previously demonstrated an advantage on cardiac toxicity, with a significantly lower rate of atrial fibrillation or flutter, which is a BTK classwide problem.